Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
Article By:
T.J. Hayes
Monday, September 9, 2019 7:36 PM EDT
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB
Bristol-Myers Passes $74 Bln Deal’s First Big Exam
Article By:
Lipper Alpha Insight
Tuesday, August 27, 2019 4:24 AM EDT
Bristol-Myers Squibb boss Giovanni Caforio can heave a sigh of relief. The drugmaker, valued at $76 billion at Friday’s close, is stretching to buy Celgene for almost as much again.
The Week Ahead In Biotech: Pharma Earnings Pick Up Pace
Article By:
Benzinga
Saturday, July 20, 2019 8:56 PM EDT
Biotech stocks had a relatively muted performance last week. Johnson & Johnson kickstarted the second-quarter reporting season for big pharma companies, beating forecasts and an upward adjustment to its full-year sales guidance.
Celgene Corporation Offers Compelling Growth Opportunity: Wedgewood
Thanks 63 hedge funds invest in $CELG, 12 phase III programs and $100 Billion in free cash flow over the next 10 years! Stellar!